FDA approves Otsuka’s kidney drug, paving the way for novel mechanism
The FDA yesterday approved a novel drug from Otsuka to treat a chronic, autoimmune kidney disease. The drug, called Voyxact, is part of an emerging class of drugs for IgA nephropathy, or IgAN, a disease caused by the build-up of immune antibodies in the kidneys. The condition, which leads to progressive loss of kidney function, can […]
FDA approves Otsuka’s kidney drug, paving the way for novel mechanism Read More »
